Why the study?
Does adjunctive vagus nerve stimulation improve outcomes in patients with refractory seizures?
Does adjunctive vagus nerve stimulation improve outcomes in patients with refractory seizures?
Vagus nerve stimulation is an established adjunctive treatment for drug-resistant epilepsy.
Answers are grounded in this paper and cite their sources.
Reinforces established VNS use in refractory epilepsy; leaves open optimal parameters and long-term comparative data.
Following the first encouraging human trials in 1988, 1,2 several controlled studies have demonstrated the antiepileptic efficacy of adjunctive vagus nerve stimulation (VNS) in patients suffering from refractory seizures. [3] [5][6][7] Accordingly, VNS was approved in Europe in 1994 as an antiepileptic treatment for patients with generalised or focal drug-resistant epilepsy. In 1997, the US Food and Drug Administration (FDA) approved VNS as an adjunctive antiepileptic treatment for patients over 12 years of age suffering from drug-resistant partial epilepsy.
No takes yet. Share an insight, caveat, or question.
Montavont et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: